Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study.

Abstract

BACKGROUND:

Clinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy.

METHODS:

We evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. We collected data on clinical symptoms, laboratory tests, radiological characteristics, viral load, anti-SARS-CoV-2 antibodies, treatment, and outcome.

RESULTS:

In mid-June 2021, 36 patients with delta variant infection were identified in Shenzhen. The most common symptoms at illness onset were cough (30.6%), fever (22.2%), myalgia (16.7%), and fatigue (16.7%). A small number of patients in this study had underlying diseases, including diabetes (5.6%) and hypertension (8.3%). The application of BRII-196 and BRII-198 can rapidly increase anti-SARS-CoV-2 IgG. The median peak IgG levels in the antibody treatment group were 32 times higher than those in the control group (P < 0.001). The time from admission to peak IgG levels in the antibody treatment group (mean: 10.2 days) was significantly shorter than that in the control group (mean: 17.7 days). Chest CT score dropped rapidly after antibody therapy, with a mean duration of 5.74 days from admission to peak levels.

CONCLUSION:

The results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection.

• Authors: Xuejiao Liao, Dapeng Li, Jie Liu, Zhi Liu, Zhenghua Ma, Jingke Dong, Xiangyi Yang, Dan Shu, Jing Yuan, Lei Liu, Zheng Zhang
• Journal: Virology journal (Virol J) Vol. 19 Issue 1 Pg. 218 (12 15 2022) ISSN: 1743-422X [Electronic] England
• PMID: 36522677 (Publication Type: Observational Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• romlusevimab
• amubarvimab
• Antibodies, Monoclonal
• Antibodies, Viral
• Immunoglobulin G

Topics

• Humans
• SARS-CoV-2
• COVID-19
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Viral
• Immunoglobulin G